Inhibition of human glutathione transferases by multidrug resistance chemomodulators in vitro

Abstract

Reversal of the drug-resistance phenotype in cancer cells usually involves the use of a chemomodulator that inhibits the function of a resistance-related protein. The aim of this study was to investigate the effects of MDR chemomodulators on human recombinant glutathione S-transferase (GSTs) activity. IC₅₀ values for 15 MDR chemomodulators were determined using 1-chloro-dinitrobenzene (CDNB), cumene hydroproxide (CuOOH) and anticancer drugs as substrates. GSTs A1, P1 and M1 were inhibited by O⁶-benzylguanine (IC₅₀s around 30 μM), GST P1-1 by sulphinpyrazone (IC₅₀ = 66 μM), GST A1-1 by sulphasalazine, and camptothecin (34 and 74 μM respectively), and GST M1-1 by sulphasalazine, camptothecin and indomethacin (0.3, 29 and 30 μM respectively) using CDNB as a substrate. When ethacrynic acid (for GST P1-1), CuOOH (for A1-1) and 1,3-bis (2-chloroethyl)-1-nitrosourea (for GST M1-1) were used as substrates, these compounds did not significantly inhibit the GST isoforms. However, progesterone was a potent inhibitor of GST P1-1 (IC₅₀ = 1.4 μM) with ethacrynic acid as substrate. These results suggest that the target of chemomodulators in vivo could be a specific resistance-related protein.

Keywords::

• Glutathione S-transferases
• P-glycoprotein
• chemomodulators
• multidrug resistance
• O⁶-benzylguanine
• BCNU
• inhibition

Acknowledgements

The International Program in Chemical Sciences (IPICS-ZIM01), Uppsala University, Sweden, and the International Foundation for Science (F/3413-01), Stockholm, Sweden supported this study. We thank Prof. Bengt Mannervik (Department of Biochemistry, Biomedical Centre, Uppsala University, Sweden) for the kind donation of E. coli clones that express human recombinant GSTs.